Ambalal Sarabhai Enterprises Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Ambalal Sarabhai Enterprises carries a disclosed but persistently entangled record: related-party loans with no repayment schedule, a stack of legacy disputes, and volatile cash flows that have kept dividends at zero for seven years. The statutory audit is clean and the auditor rotated without incident, but the real weight sits in the subsidiary channel, where loans, guarantees, and fresh shareholder approvals keep capital flowing to entities whose recoverability the company itself has provisioned against.

Key findings

  1. On-demand loans to subsidiaries carry no repayment schedule and a ₹5.33 crore provision Major - The company seeks shareholder approval at the FY26 AGM for up to ₹10 crore each in fresh financial assistance to Synbiotics Limited, Asence Pharma Private Limited, and Systronics India Limited. As at 31 March 2024, standalone loans to subsidiaries, joint ventures, and associates totalled 14.59 crore, repayable on demand with no fixed schedule. The auditor reported a net subsidiary loan balance of 7.51 crore after a provision of ₹5.33 crore.
  2. A multi-year stack of disputed tax and duty demands sits alongside a legacy guarantee dispute Minor - Disputed income tax dues stood at 5.52 crore (ITAT), 1.74 crore (CIT(A)), ₹7.24 lakh (HC), and 2.91 crore (AO) as of 31 March 2024, with amounts paid under protest rising to ₹47.26 lakh. A guarantee invocation notice from International Asset Reconstruction Company, demanding ₹7.82 crore plus interest at 18.50% per annum from 27 June 1989, remains unaccepted by the company. The company is pursuing recovery of a ₹30 crore decree from Swastik Surfactants Limited through an execution application in Kalol District Court.
  3. Promoter family holds executive roles with minimum-payout guarantees, while the MD draws Re.1 from the listed entity Minor - Mr. Kartikeya V. Sarabhai (Executive Chairman) and Mr. Mohal K. Sarabhai (Managing Director) are father and son, disclosed across annual reports from FY21 through FY26. The Chairman's re-appointment from 01.04.2027 guarantees full salary and reimbursements even in absence of profits. The Managing Director is paid a token Re.1 per month from the listed entity and draws remuneration from four other group entities.
  4. Operating cash flow is volatile, dividends are absent for seven years, and standalone FY26 shows a large new loan alongside fresh borrowings Minor - No dividend was recommended for any year from FY20 through FY26. Consolidated CFO/PAT was -3.57x in FY25 and 0.50x in FY23, recovering to 0.75x in FY26. Standalone cash flow for FY26 shows Loans Given of 4.23 crore against ₹18.86 lakhs in FY25, and Proceeds from Long Term Borrowings of 4 crore against nil in FY25.
  5. Statutory auditor rotated after a five-year tenure with no resignations or adverse actions Clean - Khandhar & Associates served from at least FY20 through FY22, and shareholders approved Sorab S. Engineer & Co. at the 22 September 2022 AGM with 99.99% votes in favour for a five-year term. CARO clause (xviii) confirms no resignation of statutory auditors during FY23, FY25, or FY26.

What to watch

Bottom line: This is a disclosed and audited record where the statutory audit is clean and the auditor rotated without friction. The character of the risk is structural: a web of on-demand loans, guarantees, and fresh shareholder approvals that keeps capital flowing to subsidiaries whose recoverability the company itself has provisioned against, while cash generation remains too thin to support a dividend. Watch the AGM votes on subsidiary financial assistance and promoter re-appointments, and whether the ₹30 crore decree from Swastik Surfactants ever converts to cash.